© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
AbbVie has applied for new indication for Viekira Pak: to treat those with genotype 1b of virus and compensated cirrhosis without ribavirin.
AbbVie’s Viekira Pak cured all people with genotype 1b of hepatitis C and compensated cirrhosis in a recent late-stage trial.
Olysio plus Norvir and two investigatory drugs led to a perfect cure rate among people with genotype 1b of hepatitis C in a recent small trial...
AbbVie’s combination tablet of ombitasvir, paritaprevir and ritonavir cured 95 percent of treatment-naive Japanese adults with genotype...
Bristol-Myers Squibb’s daclatasvir and asunaprevir cured 81 percent to 87 percent of people with genotype 1b of hepatitis C in a recent Phase...
Twenty-four weeks of daclatasvir and asunaprevir, without interferon or ribavirin, cured 87 percent of people with genotype 1b of hepatitis C....
AbbVie’s interferon-free regimen of three direct-acting antivirals, plus ribavirin, cured 96 percent of people with hepatitis C in a la...
Merck?s dual combination hepatitis C therapy boasted near-perfect cure rates in an early trial including people with genotypes 1a and 1b.
AbbVie’s investigational triple combination hepatitis C therapy cured an average of 98 percent of those with genotype 1b of the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
